Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 54Breast Neoplasms 43Neoplasms 4Salivary Gland Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Advanced Breast Cancer 2Recurrence 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Inflammatory Breast Neoplasms 1Hormone-sensitive Metastatic Breast Cancer 1Hormone Sensitive Prostate Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasms, Male 1Anatomic Stage I Breast Cancer AJCC v8 1

Interventions

acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Nivolumab 1Leuprolide 1Goserelin 1Docetaxel 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hormone Sensitive Prostate Cancer × Goserelin × Clear all
NCT04126070 2026-05-27

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
47 enrolled 16 charts
Genitourinary

Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡